Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Erwin

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Diagnostic Microbiology and Infectious Disease|November 1, 1992
Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycinR N Jones, M E Erwin
Journal of Clinical Microbiology|May 1, 1992
Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporinR N Jones, M E Erwin
Diagnostic Microbiology and Infectious Disease|October 29, 1998
In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study GroupR N Jones, M E Erwin
Journal of Clinical Microbiology|May 1, 1992
Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar mediumM E Erwin, R N Jones
Diagnostic Microbiology and Infectious Disease|August 1, 1992
In vitro activity of CP-74667 compared with four other fluoroquinolonesR N Jones, M E Erwin
Diagnostic Microbiology and Infectious Disease|July 25, 2000
Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study GroupR N Jones, M E Erwin
Antimicrobial Agents and Chemotherapy|January 1, 1992
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporinR N Jones, M E Erwin
Journal of Clinical Microbiology|December 1, 1991
Disk diffusion susceptibility test interpretive criteria for GR69153, a new catechol-substituted cephalosporinR N Jones, M E Erwin
Diagnostic Microbiology and Infectious Disease|January 1, 1992
New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteriaR N Jones, M E Erwin, M Bale
Diagnostic Microbiology and Infectious Disease|February 1, 1996
Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trialsS Worth, M E Erwin, R N Jones
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Diagnostic Microbiology and Infectious Disease|November 1, 1992
Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycinR N Jones, M E Erwin
Journal of Clinical Microbiology|May 1, 1992
Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporinR N Jones, M E Erwin
Diagnostic Microbiology and Infectious Disease|October 29, 1998
In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study GroupR N Jones, M E Erwin
Journal of Clinical Microbiology|May 1, 1992
Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar mediumM E Erwin, R N Jones
Diagnostic Microbiology and Infectious Disease|August 1, 1992
In vitro activity of CP-74667 compared with four other fluoroquinolonesR N Jones, M E Erwin
Diagnostic Microbiology and Infectious Disease|July 25, 2000
Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study GroupR N Jones, M E Erwin
Antimicrobial Agents and Chemotherapy|January 1, 1992
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporinR N Jones, M E Erwin
Journal of Clinical Microbiology|December 1, 1991
Disk diffusion susceptibility test interpretive criteria for GR69153, a new catechol-substituted cephalosporinR N Jones, M E Erwin
Diagnostic Microbiology and Infectious Disease|January 1, 1992
New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteriaR N Jones, M E Erwin, M Bale
Diagnostic Microbiology and Infectious Disease|February 1, 1996
Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trialsS Worth, M E Erwin, R N Jones
Pageof 9